Arcturus Therapeutics (ARCT) Competitors $11.39 -0.52 (-4.37%) Closing price 08/11/2025 04:00 PM EasternExtended Trading$11.59 +0.20 (+1.76%) As of 08/11/2025 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsBuy This Stock ARCT vs. COGT, CDTX, ABCL, CVAC, CALT, NTLA, HROW, PRAX, AVDL, and PAHCShould you be buying Arcturus Therapeutics stock or one of its competitors? The main competitors of Arcturus Therapeutics include Cogent Biosciences (COGT), Cidara Therapeutics (CDTX), AbCellera Biologics (ABCL), CureVac (CVAC), Calliditas Therapeutics AB (publ) (CALT), Intellia Therapeutics (NTLA), Harrow (HROW), Praxis Precision Medicines (PRAX), Avadel Pharmaceuticals (AVDL), and Phibro Animal Health (PAHC). These companies are all part of the "pharmaceutical products" industry. Arcturus Therapeutics vs. Its Competitors Cogent Biosciences Cidara Therapeutics AbCellera Biologics CureVac Calliditas Therapeutics AB (publ) Intellia Therapeutics Harrow Praxis Precision Medicines Avadel Pharmaceuticals Phibro Animal Health Arcturus Therapeutics (NASDAQ:ARCT) and Cogent Biosciences (NASDAQ:COGT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation. Does the media prefer ARCT or COGT? In the previous week, Cogent Biosciences had 23 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 33 mentions for Cogent Biosciences and 10 mentions for Arcturus Therapeutics. Arcturus Therapeutics' average media sentiment score of 0.44 beat Cogent Biosciences' score of 0.08 indicating that Arcturus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcturus Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cogent Biosciences 4 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral Which has preferable valuation and earnings, ARCT or COGT? Arcturus Therapeutics has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcturus Therapeutics$152.31M2.03-$80.94M-$2.53-4.50Cogent BiosciencesN/AN/A-$255.86M-$1.78-6.14 Do analysts recommend ARCT or COGT? Arcturus Therapeutics currently has a consensus price target of $50.80, suggesting a potential upside of 346.01%. Cogent Biosciences has a consensus price target of $18.70, suggesting a potential upside of 71.09%. Given Arcturus Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Arcturus Therapeutics is more favorable than Cogent Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcturus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Cogent Biosciences 0 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.82 Do institutionals and insiders have more ownership in ARCT or COGT? 94.5% of Arcturus Therapeutics shares are held by institutional investors. 15.3% of Arcturus Therapeutics shares are held by company insiders. Comparatively, 7.3% of Cogent Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is ARCT or COGT more profitable? Cogent Biosciences has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -47.47%. Arcturus Therapeutics' return on equity of -27.41% beat Cogent Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Arcturus Therapeutics-47.47% -27.41% -19.01% Cogent Biosciences N/A -223.82%-89.44% Which has more risk & volatility, ARCT or COGT? Arcturus Therapeutics has a beta of 2.26, suggesting that its stock price is 126% more volatile than the S&P 500. Comparatively, Cogent Biosciences has a beta of 0.36, suggesting that its stock price is 64% less volatile than the S&P 500. SummaryArcturus Therapeutics beats Cogent Biosciences on 11 of the 15 factors compared between the two stocks. Get Arcturus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARCT vs. The Competition Export to ExcelMetricArcturus TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$323.01M$3.00B$5.48B$9.72BDividend YieldN/A2.28%4.59%4.13%P/E Ratio-4.5017.0529.7524.63Price / Sales2.03347.15454.25102.60Price / CashN/A40.7324.8427.99Price / Book1.288.898.605.76Net Income-$80.94M-$54.75M$3.26B$264.95M7 Day Performance-3.72%-2.71%-0.29%0.01%1 Month Performance-17.34%4.43%2.16%1.28%1 Year Performance-39.89%19.64%44.84%26.11% Arcturus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARCTArcturus Therapeutics2.8678 of 5 stars$11.39-4.4%$50.80+346.0%-37.0%$323.01M$152.31M-4.50180News CoverageEarnings ReportAnalyst UpgradeHigh Trading VolumeCOGTCogent Biosciences2.8651 of 5 stars$12.05+5.7%$18.70+55.2%+27.4%$1.30BN/A-6.5580Earnings ReportCDTXCidara Therapeutics3.3759 of 5 stars$62.46-0.7%$57.29-8.3%+425.0%$1.27B$1.27M-2.1290News CoverageEarnings ReportABCLAbCellera Biologics3.2054 of 5 stars$4.34+2.4%$8.75+101.6%+67.9%$1.27B$28.83M-7.75500News CoverageEarnings ReportAnalyst ForecastCVACCureVac4.3659 of 5 stars$5.46+0.9%$6.83+25.2%+65.5%$1.21B$579.18M5.93880Upcoming EarningsCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180NTLAIntellia Therapeutics4.5503 of 5 stars$12.12+5.5%$33.37+175.3%-50.0%$1.19B$57.88M-2.32600News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionHROWHarrow2.3336 of 5 stars$33.42+7.0%$63.83+91.0%-6.1%$1.15B$199.61M-59.68180PRAXPraxis Precision Medicines1.6592 of 5 stars$51.09-5.5%$94.11+84.2%-11.5%$1.10B$8.55M-4.77110Analyst RevisionGap DownHigh Trading VolumeAVDLAvadel Pharmaceuticals2.6079 of 5 stars$11.26+1.6%$18.33+62.8%-17.5%$1.07B$169.12M-41.7070News CoveragePositive NewsEarnings ReportAnalyst UpgradeAnalyst RevisionPAHCPhibro Animal Health4.1499 of 5 stars$27.14+3.9%$24.40-10.1%+62.1%$1.06B$1.02B34.801,940Positive News Related Companies and Tools Related Companies Cogent Biosciences Alternatives Cidara Therapeutics Alternatives AbCellera Biologics Alternatives CureVac Alternatives Calliditas Therapeutics AB (publ) Alternatives Intellia Therapeutics Alternatives Harrow Alternatives Praxis Precision Medicines Alternatives Avadel Pharmaceuticals Alternatives Phibro Animal Health Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARCT) was last updated on 8/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThe stealth altcoin the financial world is underestimatingThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcturus Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcturus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access